

Jens Plag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6624795/publications.pdf>

Version: 2024-02-01

33
papers

2,029
citations

471509

17
h-index

302126

39
g-index

39
all docs

39
docs citations

39
times ranked

2765
citing authors

#	ARTICLE	IF	CITATIONS
1	Mental Health in German Paralympic Athletes During the 1st Year of the COVID-19 Pandemic Compared to a General Population Sample. <i>Frontiers in Sports and Active Living</i> , 2022, 4, 870692.	1.8	12
2	Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression. <i>Molecular Psychiatry</i> , 2021, 26, 4179-4190.	7.9	58
3	Associations between COVID-19 related media consumption and symptoms of anxiety, depression and COVID-19 related fear in the general population in Germany. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 283-291.	3.2	251
4	Longitudinal changes in anxiety and psychological distress, and associated risk and protective factors during the first three months of the COVID-19 pandemic in Germany. <i>Brain and Behavior</i> , 2021, 11, e01964.	2.2	112
5	Longitudinal changes of anxiety and depressive symptoms during the COVID-19 pandemic in Germany: The role of pre-existing anxiety, depressive, and other mental disorders. <i>Journal of Anxiety Disorders</i> , 2021, 79, 102377.	3.2	121
6	Efficacy of temporally intensified exposure for anxiety disorders: A multicenter randomized clinical trial. <i>Depression and Anxiety</i> , 2021, 38, 1169-1181.	4.1	19
7	COVID-19 vaccine hesitancy and related fears and anxiety. <i>International Immunopharmacology</i> , 2021, 97, 107724.	3.8	236
8	Fronto-lateral alpha power asymmetry in panic disorder. <i>International Journal of Psychophysiology</i> , 2021, 167, 69-76.	1.0	4
9	Working out the worries: A randomized controlled trial of high intensity interval training in generalized anxiety disorder. <i>Journal of Anxiety Disorders</i> , 2020, 76, 102311.	3.2	16
10	Development of the COVID-19-Anxiety Questionnaire and first psychometric testing. <i>BJPsych Open</i> , 2020, 6, e91.	0.7	30
11	An investigation of genetic variability of DNA methyltransferases DNMT3A and 3B does not provide evidence for a major role in the pathogenesis of panic disorder and dimensional anxiety phenotypes. <i>Journal of Neural Transmission</i> , 2020, 127, 1527-1537.	2.8	2
12	Risk, resilience, psychological distress, and anxiety at the beginning of the COVID-19 pandemic in Germany. <i>Brain and Behavior</i> , 2020, 10, e01745.	2.2	304
13	P50, N100, and P200 Sensory Gating in Panic Disorder. <i>Clinical EEG and Neuroscience</i> , 2020, 51, 317-324.	1.7	8
14	Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. <i>Journal of Anxiety Disorders</i> , 2019, 68, 102149.	3.2	36
15	Performance anxiety in professional musicians: a systematic review on prevalence, risk factors and clinical treatment effects. <i>Psychological Medicine</i> , 2019, 49, 2287-2306.	4.5	75
16	Heart rate variability in patients with agoraphobia with or without panic disorder remains stable during CBT but increases following in-vivo exposure. <i>Journal of Anxiety Disorders</i> , 2019, 64, 16-23.	3.2	4
17	Reduced Sensitivity to Non-Fear-Related Stimulus Changes in Panic Disorder. <i>Neuropsychobiology</i> , 2019, 78, 31-37.	1.9	9
18	High-Intensity Interval Training in Panic Disorder Patients. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 184-187.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Increasing physical activity and healthy diet in outpatients with mental disorders: a randomized-controlled evaluation of two psychological interventions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 529-542.	3.2	10
20	Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. <i>Journal of Psychiatric Research</i> , 2018, 101, 34-41.	3.1	24
21	Patients' characteristics and their influence on course of fear during agoraphobic symptom provocation: may SS(N)RI treatment compensate unfavorable individual preconditions?. <i>Nordic Journal of Psychiatry</i> , 2018, 72, 325-335.	1.3	2
22	Learn to forget: Does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia?. <i>Journal of Psychiatric Research</i> , 2018, 105, 153-163.	3.1	10
23	D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 501.	11.0	236
24	Physical activity in outpatients with mental disorders: status, measurement and social cognitive determinants of health behavior change. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 639-650.	3.2	12
25	Clinical and neurobiological effects of aerobic exercise in dental phobia: A randomized controlled trial. <i>Depression and Anxiety</i> , 2017, 34, 1040-1048.	4.1	8
26	Facing the fear – clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. <i>European Neuropsychopharmacology</i> , 2016, 26, 431-444.	0.7	19
27	AEROBIC EXERCISE TRAINING FACILITATES THE EFFECTIVENESS OF COGNITIVE BEHAVIORAL THERAPY IN PANIC DISORDER. <i>Depression and Anxiety</i> , 2015, 32, 221-228.	4.1	60
28	Who is stressed? A pilot study of salivary cortisol and alpha-amylase concentrations in agoraphobic patients and their novice therapists undergoing in vivo exposure. <i>Psychoneuroendocrinology</i> , 2014, 49, 280-289.	2.7	30
29	Effect of combined cognitive-behavioural therapy and endurance training on cortisol and salivary alpha-amylase in panic disorder. <i>Journal of Psychiatric Research</i> , 2014, 58, 12-19.	3.1	25
30	Acute onset of panic attacks after transdermal estrogen replacement. <i>General Hospital Psychiatry</i> , 2014, 36, e7.	2.4	4
31	Baseline and acute changes in the HPA system in patients with anxiety disorders: the current state of research. <i>Neuropsychiatry</i> , 2013, 3, 45-62.	0.4	8
32	Distinct Panicogenic Activity of Sodium Lactate and Cholecystokinin Tetrapeptide in Patients with Panic Disorder. <i>Current Pharmaceutical Design</i> , 2012, 18, 5619-5626.	1.9	5
33	d-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. <i>Journal of Psychiatric Research</i> , 2011, 45, 1042-1047.	3.1	81